NCNA
NuCana plc
NASDAQ · Healthcare · Biotechnology · GB
$1.40
−2.10%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +29.5%
- EBIT
- +36.3%
- EPS
- +90.9%
- Free cash flow
- +74.1%
- Operating cash flow
- +74.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +8.6%
- EBIT
- +11.8%
- Net income
- -54.5%
- EPS
- +98.9%
- Free cash flow
- +60.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026